Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 1, 2013, Pages 270-275

  Choi, Bryan D ^a   Kuan, Chien Tsun ^a   Cai, Mingqing ^b   Archer, Gary E ^a   Mitchell, Duane A ^a   Gedeon, Patrick C ^a,c   Sanchez Perez, Luis ^a   Pastan, Ira ^d   Bigner, Darell D ^a   Sampson, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c Duke University   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Blood brain barrier; Central nervous system; Immunomodulation; Therapeutics

Indexed keywords

BI SPECIFIC T CELL ENGAGER; BISPECIFIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 8; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG PURIFICATION; GLIOBLASTOMA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TREATMENT RESPONSE; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, BISPECIFIC; BRAIN NEOPLASMS; CHROMATOGRAPHY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ESCHERICHIA COLI; FLOW CYTOMETRY; GLIOMA; IMMUNOTHERAPY; MICE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURFACE PLASMON RESONANCE; T-LYMPHOCYTES; TREATMENT OUTCOME;

MUS;

EID: 84871965330     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1219817110     Document Type: Article

References (33)

1. Stummer W, et al. (2000) Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: A prospective study in 52 consecutive patients. J Neurosurg 93(6):1003-1013. (Pubitemid 32800611)
2. Stupp R, et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459-466.
3. Imperato JP, Paleologos NA, Vick NA (1990) Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 28(6):818-822.
4. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480(7378):480-489.
5. Dudley ME, Rosenberg SA (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3(9):666-675. (Pubitemid 37328821)
6. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: Moving beyond current vaccines. Nat Med 10(9):909-915. (Pubitemid 39273730)
7. Morgan RA, et al. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796):126-129. (Pubitemid 44547756)
8. Dudley ME, et al. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594):850-854. (Pubitemid 35231542)
9. Suntharalingam G, et al. (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355(10):1018-1028. (Pubitemid 44343545)
10. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23(9):1126-1136. (Pubitemid 41486394)
11. Bargou R, et al. (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321(5891):974-977.
12. Choi BD, et al. (2011) Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther 11(7):843-853.
13. Baeuerle PA, Reinhardt C (2009) Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 69(12):4941-4944.
14. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M (2010) Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: Case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 18(4):666-668.
15. Morgan RA, et al. (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18(4):843-851.
16. Klinger M, et al. (2012) Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119(26):6226-6233.
17. Heslop HE (2010) Safer CARS. Mol Ther 18(4):661-662.
18. Choi BD, et al. (2009) EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 19(4):713-723.
19. Bluemel C, et al. (2010) Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother 59(8):1197-1209.
20. Kuan CT, et al. (2000) Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. Int J Cancer 88(6):962-969.
21. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA (2006) Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 43(6):763-771. (Pubitemid 41785405)
22. Yang I, et al. (2010) CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci 17(11):1381-1385.
23. Lohr J, et al. (2011) Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res 17(13):4296-4308.
24. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22(3):659-661. (Pubitemid 351348146)
25. Slamon DJ, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783-792. (Pubitemid 32222155)
26. Hurwitz H, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342. (Pubitemid 38702844)
27. Le Gall F, Reusch U, Moldenhauer G, Little M, Kipriyanov SM (2004) Immunosuppressive properties of anti-CD3 single-chain Fv and diabody. J Immunol Methods 285(1):111-127. (Pubitemid 38186590)
28. Dreier T, et al. (2003) T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol 170(8):4397-4402. (Pubitemid 36428210)
29. Grosse-Hovest L, et al. (2005) Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo. Int J Cancer 117(6):1060-1064. (Pubitemid 41688586)
30. Scott AM, et al. (2007) A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 104(10):4071-4076. (Pubitemid 47181580)
31. Zalutsky MR, Moseley RP, Coakham HB, Coleman RE, Bigner DD (1989) Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 49(10):2807-2813. (Pubitemid 19143420)
32. Engelhardt B, Ransohoff RM (2005) The ins and outs of T-lymphocyte trafficking to the CNS: Anatomical sites and molecular mechanisms. Trends Immunol 26(9):485-495. (Pubitemid 41139258)
33. Kuhn C, et al. (2011) Human CD3 transgenic mice: Preclinical testing of antibodies promoting immune tolerance. Sci Transl Med 3(68):68ra10.